JPRN-UMIN000025339招募中未知
A retrospective Multicenter Study to Assess the Safety and Efficacy of Robot-assisted (da Vinci surgical system, DVSS) Partial Nephrectomy for small renal tumors. - A retrospective Multicenter Study to Assess the Safety and Efficacy of Robot-assited Partial Nephrectomy
Kobe University Graduate School of Medicine Division of Urology, Department of Surgery Related0 个研究点目标入组 900 人开始时间: 2016年12月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who deny the enrollment of this study
研究者
相似试验
进行中（未招募）
1 期
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisCTIS2023-505678-14-00AbbVie Deutschland GmbH & Co. KG207
进行中（未招募）
1 期
A Multicenter, Long-term Follow-up Study of the Safety and Efficacy ofBOTOX® (Botulinum Toxin Type A) in Patients with Urinary Incontinence Due to Neurogenic bladderrinary incontinence due to neurogenic detrusor overactivityMedDRA version: 13.1Level: PTClassification code 10029279Term: Neurogenic bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2009-009216-53-BEAllergan Ltd500
进行中（未招募）
1 期
ong-Term Follow up study of BOTOX in patients with Overactive Bladder with urinary IncontinenceEUCTR2009-013089-26-GBAllergan Ltd829
进行中（未招募）
不适用
A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Patients with Urinary Incontinence Due to Neurogenic bladderrinary incontinence due to neurogenic detrusor overactivityMedDRA version: 13.1Level: PTClassification code 10029279Term: Neurogenic bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2009-009216-53-ATAllergan Ltd500
进行中（未招募）
1 期
A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Patients with Urinary Incontinence Due to Neurogenic BladderEUCTR2009-009216-53-SKAllergan Ltd500